Adma Biologics Inc (NASDAQ: ADMA) is 274.12% higher on its value in year-to-date trading and has touched a low of $3.06 and a high of $19.34 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $17.29 in the last trading session, with the day’s loss setting it -0.38%.
Currently trading at $16.91, the stock is -2.97% and 15.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.12 million and changing -2.20% at the moment leaves the stock 99.52% off its SMA200. ADMA registered 342.67% gain for a year compared to 6-month gain of 171.86%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.80% loss in the last 1 month and extending the period to 3 months gives it a 61.05%, and is 0.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.45% over the week and 4.57% over the month.
Adma Biologics Inc (ADMA) has around 624 employees, a market worth around $3.94B and $330.24M in sales. Current P/E ratio is 120.27 and Fwd P/E is 25.82. Profit margin for the company is 10.53%. Distance from 52-week low is 452.61% and -12.56% from its 52-week high. The company has generated returns on investments over the last 12 months (10.59%).
Adma Biologics Inc quarterly earnings per share for the current quarter are estimated at 0.13 with sales reaching $105.97M over the same period.The EPS is expected to grow by 471.15% this year, but quarterly earnings will post 57.10% year-over-year.
338.0 institutions hold shares in Adma Biologics Inc (ADMA), with institutional investors hold 82.81% of the company’s shares. The shares outstanding are 226.06M, and float is at 225.19M with Short Float at 4.00%. Institutions hold 80.67% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.1462 of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.3426 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.7546 and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8996 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Guiheen Lawrence P., the company’s Director. SEC filings show that Guiheen Lawrence P. sold 9,000 shares of the company’s common stock on Sep 09 ’24 at a price of $18.47 per share for a total of $0.17 million. Following the sale, the insider now owns 0.15 million shares.
Still, SEC filings show that on Aug 30 ’24, Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) disposed off 24,150 shares at an average price of $16.90 for $0.41 million. The insider now directly holds 449,088 shares of Adma Biologics Inc (ADMA).
